Local treatment for pulmonary oligometastases (one to five lesions) using metastasectomy or stereotactic ablative radiotherapy (SABR) was investigated in a cohort that received multidisciplinary tumor board-based treatment decisions. The first choice of treatment was surgery; SABR was recommended in cases of adverse clinical factors. Propensity score-adjusted and unadjusted overall survival was the primary end point; local control and time to failure of a local-only treatment strategy were also analyzed. With a minimum follow-up time of 5.8 years, the 5-year overall survival rate was 41% for surgery (n ¼ 68) and 45% for SABR (n ¼ 42). Again not different for the two modalities, 40% of patients were free from failure of a local-only treatment strategy, and 20% were free from any progression at 5 years. The 5-year local control rate was 83% for SABR and 81% for surgery. Despite treatment selection clearly disadvantaging SABR against surgery, even unadjusted outcome was not better when pulmonary oligometastases were surgically removed rather than irradiated.
Introduction
Intuition suggests that pulmonary metastasectomy (PME) with clear margins would entail the best odds of cure for patients with limited pulmonary metastases (oligometastases) from solid tumors and is recommended for various malignancies in guidelines. Stereotactic ablative radiotherapy (SABR) is frequently regarded as the second-best option in cases with any arguments against surgery: higher age, compromised physical condition, unfavorable central location of a nodule in the lungs, or higher number of previous metastasis-directed (local) treatments or shorter metastasis-free interval (MFI). Randomized or population-based studies comparing PME with SABR for pulmonary oligometastases are unavailable, as are evidence-increasing comparisons between any local metastasis-directed treatments and systemic approaches or cohorts with long-term follow-up. [1] [2] [3] We present long-term results from our previously published consecutive cohort treated with PME or SABR for pulmonary oligometastases from various cancers. 4 The primary purpose of the present study was to assess long-term overall survival (OS), local recurrence (LR) of treated metastases, progression-free-survival, and time to failure of local-only treatment strategy. In addition, the influence of lesion size of index metastases on survival and local control (LC) was explored in an attempt to gain exploratory information concerning choice of the optimal point in time for local treatment of metastases.
Methods
All consecutive patients who received a recommendation at our institution's multidisciplinary thoracic tumor board for a local metastasis-directed treatment with curative intent for pulmonary metastases between 2007 and 2010 were included and retrospectively analyzed. Primary tumors and eventual other metastases had been removed in all patients, and the patients received a recommendation for a local-only treatment strategy with curative intention. No patient had received biologically targeted or immune therapy. The standard first-choice recommendation was to surgically remove all lung metastases. SABR for all lesions was recommended in the case of arguments against surgery, typically consisting of a combination of higher age, compromised physical condition, unfavorable central location of a nodule in the lungs, or a higher number of previous metastasis-directed (local) treatments or shorter MFI. Patients were followed-up at 3-to 4-month intervals with a computed tomography scan of the thorax and abdomen and rediscussed at the tumor board in the case of progression. Survival information was double-checked by family physicians. OS from index treatment to death or last survival information comparing SABR with PME was estimated by using both univariable and propensity score-adjusted Cox regression analysis. The propensity score was based on age, primary tumor, prior chemotherapy, number of prior local treatments for metastases, number of lesions, and MFI (duration from discovery of primary tumor to first detection of any metastases). Cumulative incidence of LR was estimated from index treatment to local failure triggering further treatment at the multidisciplinary conference, with death or failure of local-only treatment strategy constituting competing risks. As all patients were discussed at the multidisciplinary thoracic tumor board before further treatment; time to failure of local-only treatment strategy was measured from index treatment to board recommendation against further local-only treatment (no matter in which organs the new metastases were located). To estimate the impact on LR or OS of the delay from first detection of an index metastasis to treatment with SABR or PME, we also tested whether these two end points were influenced by lesion size. Lesion size was entered as a continuous variable, so that a hazard rate (HR) higher than 1 would depict worse outcome in larger lesions. The study was approved with an informed consent waiver by the university's institutional review board. Analyses were done with STATA software, version 13 (StataCorp LP, College Station, TX).
Results
A total of 110 patients were included, and the median follow-up time was 7.6 years (5.8-9.8). The median ages were 70 and 61 years (p < 0.001) for SABR and PME, respectively, and the respective MFI values were 12.7 and 18.0 months (p ¼ 0.045), both disadvantaging SABR (Table 1) . Actuarial outcome data are displayed in Table 2 , and Figure 1 shows unadjusted OS curves from the date of index treatment. The 5-year OS rates were 45% for patients treated with SABR and 41% after PME, respectively. The unadjusted HR of OS for SABR versus PME was 1.11 (95% confidence interval [CI]: 0.70-1.75); it decreased to 0.76 (95% CI: 0.38-1.54) after propensity score adjustment (neither was significant). The actuarial LR rates at 5 years were 17% for SABR and 19% for PME, and the HR at competing risk analysis for LR was 0.80 (95% CI: 0.24-2.65) for SABR versus PME. Although about half of the patients had progressed by 1 year, rendering progression-free survival rates of 49% and 56% for SABR and PME, respectively, 20% of patients had remained free from any progression at 5 years and 40% had not failed a local-only strategy for management of their metastatic disease at 5 years (see Table 2 ), meaning that they had not received any systemic treatment since index local treatment. Lesion size did not influence either LC (HR ¼ 1.03, 95% CI: 0.73 -1.45) or OS (HR ¼ 0.85, 95% CI: 0.69 -1.04), but the HR for OS pointed in the direction of more favorable survival with increasing lesion size.
Discussion
Despite higher age and shorter MFI suggesting higher baseline risk for death after SABR compared with PME, even unadjusted reanalysis at almost 6 years' minimum follow-up time of a consecutive cohort still does not provide an argument supporting the notion that surgery for pulmonary oligometastases would result in better survival or LC compared with SABR. 4 Although these results must be interpreted with caution on account of the limited sample size, they are strikingly comparable to those of the largest retrospective PME analysis, according to which the 5-and 10-year survival rates were 36% and 26%, respectively. 5 Also, we did not find any signals suggesting that treating smaller rather than larger metastatic lesions would entail more favorable survival or LC, challenging the frequently adhered to notion that local treatment of metastases should be initiated as early as possible. Rather, postponing treatment for asymptomatic metastases detected during follow-up until they are demarcated as truly limited in number could be a reasonable strategy to identify patients with an oligometastatic disease pattern that is likely based on tumor biology and spare from useless local metastasis-directed interventions those patients who would progress to systemic failure anyway at short notice. We are presently conducting a randomized trial testing the optimal time point of SABR for pulmonary oligometastases from colorectal cancer (NCT02414334). The present analysis does not support favoring surgery over SABR; but still, it also does not provide direct evidence for using either resection or SABR for oligometastases. 1 Rigorous research comparing a primarily local treatment strategy with nonlocal treatment strategies is urgently needed to better characterize patients who might benefit from aggressive local treatment of lung metastases with the intention of cure or, at least, postponement of systemic treatment Figure 1 . Unadjusted overall survival. PME, pulmonary metastasectomy; SABR, stereotactic ablative radiation.
for as long as possible. In addition and complementary to that strategy, in an era of increasing use of molecularly targeted agents and immunotherapy for metastatic disease, there is a need for characterization of situations in which local metastasis-directed treatment would supplement such systemic treatment by effectively tackling localizable treatment resistance.
